Simulate Any Clinical Scenario with Pinpoint Accuracy

A platform for end to end decision-making in clinical development based on next-generation clinical AI technologies

Use Cases

Supporting Sponsors from Early Clinical Development to Approval

Clinical Development

  • Protocol Optimization

  • Indication Selection

  • TPP

  • PTS

  • Market Forecasting

  • Enrollment Prediction

Clinical Development

Business Development

  • Search and Evaluation - Many to Few

  • Comparative Deep Dive - Few to One

  • Asset Diligence & Valuation

  • Asset Out-licensing & Disposition

Business Development

Portfolio Management

  • Asset Prioritization

  • Asset Synergy and Overlap

  • Gaps and Opportunities

Portfolio Management

Prospectively Validated

Predicting trial results before readout, without sponsor data, with 85% accuracy on the primary endpoint

IMVOKE010:

Randomized phase III study of atezolizumab (atezo) as adjuvant monotherapy after definitive therapy of squamous cell carcinoma of the head and neck (scchn)

  • Simulated ResultsIMVOKE010 - Simulated Results Graph
  • Actual ResultsIMVOKE010 Graph 2
1
For More Evidence

By the Numbers

>10K

Data points
per patient

Over
120
Trials simulated

Over
45
Diseases

85%
Endpoint prediction accuracy

>100K
Drug & mechanism data points

350M
Lives

Explore the Power of Clinical Simulation